227 related articles for article (PubMed ID: 16954580)
1. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation.
Chitkara K; Hogrefe K; Vasa-Nicotera M; Swanson N; Gershlick AH
J Invasive Cardiol; 2006 Sep; 18(9):417-22. PubMed ID: 16954580
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents.
Baron JH; Gershlick AH; Hogrefe K; Armstrong J; Holt CM; Aggarwal RK; Azrin M; Ezekowitz M; de Bono DP
Cardiovasc Res; 2000 Jun; 46(3):585-94. PubMed ID: 10912469
[TBL] [Abstract][Full Text] [Related]
3. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
5. [The bioresorbable coronary stent: a revolution].
Koegler F; De Benedetti E
Rev Med Suisse; 2013 Apr; 9(381):775-8. PubMed ID: 23659156
[TBL] [Abstract][Full Text] [Related]
6. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
7. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
[TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
Gilchrist IC
Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
[TBL] [Abstract][Full Text] [Related]
10. Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement.
Sisk J; Palma M; Cooper C; Eltahawy E; Atallah J
Pain Physician; 2012; 15(6):479-83. PubMed ID: 23159964
[TBL] [Abstract][Full Text] [Related]
11. Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease.
Amoroso G; van Boven AJ; van Veldhuisen DJ; Tio RA; Baljé-Volkers CP; Petronio AS; van Oeveren W
J Cardiovasc Pharmacol; 2001 Oct; 38(4):633-41. PubMed ID: 11588534
[TBL] [Abstract][Full Text] [Related]
12. Eluting characteristics of a platelet glycoprotein receptor antibody using a PLLA-coated stent.
Wang GX; Yin TY; Luo LL; Hou YB; Wang YZ; Ruan CG; Guzman RP; Guidoin R
J Biomater Sci Polym Ed; 2008; 19(3):359-71. PubMed ID: 18325236
[TBL] [Abstract][Full Text] [Related]
13. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
Tcheng JE; Talley JD; O'Shea JC; Gilchrist IC; Kleiman NS; Grines CL; Davidson CJ; Lincoff AM; Califf RM; Jennings LK; Kitt MM; Lorenz TJ
Am J Cardiol; 2001 Nov; 88(10):1097-102. PubMed ID: 11703951
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
[TBL] [Abstract][Full Text] [Related]
16. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model.
Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z
J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of a novel polymer-free everolimus-eluting stent by nitrogen-doped titanium dioxide film deposition.
Park DS; Bae IH; Jeong MH; Lim KS; Sim DS; Hong YJ; Lee SY; Jang EJ; Shim JW; Park JK; Lim HC; Kim HB
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():615-623. PubMed ID: 30033294
[TBL] [Abstract][Full Text] [Related]
18. In-vitro assays of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor monoclonal antibody.
Yin T; Wang G; Ruan C; Guzman R; Guidoin R
J Biomed Mater Res A; 2007 Dec; 83(3):861-7. PubMed ID: 17567855
[TBL] [Abstract][Full Text] [Related]
19. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
[TBL] [Abstract][Full Text] [Related]
20. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
Waksman R; Pakala R
EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
